Bimagrumab

Category
biologic
Aliases
BYM338

Pharmacological Mechanism

A human monoclonal antibody against the activin type II receptors ActRIIA and ActRIIB, occupying the ligand-binding site competitively and so blocking myostatin, activin A and GDF11 signalling through Smad2/3, which relieves the negative regulation of skeletal muscle mass. PMID:29109273 verbatim: "bimagrumab binds to both ActRIIA and ActRIIB ligand binding domains in a competitive manner at the critical myostatin/activin binding site, hence preventing signal transduction through either ActRII". PMID:33264516 full text adds: "Bimagrumab is a human monoclonal antibody that blocks the ActRIIs, preventing the activity of myostatin and other negative skeletal muscle regulators".

Dosing Guidelines

Target Organ Systems

Notes

NO MOLECULAR WEIGHT IS STORED. PubChem returns PUGREST.NotFound for `bimagrumab`, and none of the three full texts read prints a kDa figure for it, so the familiar ~150 kDa IgG mass is not citable from anything fetched. That absence BLOCKS an occupancy row even though a real affinity exists, because the schema's ec50_mg_l needs the mass for the nM-to-mg/L conversion. AFFINITY, VERBATIM AND CORRECTLY ATTRIBUTED (PMID:29109273 full text, SPR against human ActRIIA-Fc and ActRIIB-Fc): "The affinity of the bimagrumab Fab for ActRIIA ( K d = 973 pM) is >50-fold lower in comparison with ActRIIB ( K d = 16 pM)". NOTE THESE ARE FAB AFFINITIES, NOT WHOLE-IgG. The same paragraph prints affinities for the LIGANDS (myostatin, activin A) and for two OTHER antibodies, CSJ089 and CQI876 — none of which belongs on this record. SINGLE-DOSE IV Cmax, verbatim from PMID:33264516 full text, established as single-dose by "The concentration-time profile following a single i.v. infusion of bimagrumab 3 or 30 mg/kg": "In older adults administered bimagrumab 3 and 30 mg/kg, mean C max was 90.7 and 982 microg/mL ... obese participants administered bimagrumab 30 mg/kg had a mean C max of 944 microg/mL". SUBCUTANEOUS BIOAVAILABILITY IS AN ESTIMATE, not a measurement: PMID:36527600 says "The absolute subcutaneous bioavailability was estimated at approximately 40%", so under R17 it is recorded here and not stored in an F slot, and it would belong to the SC route only. That paper also gives three formulations in one study — IV infusion, SC infusion and SC bolus — so any future ka or F is formulation-specific. A COMPARATOR NOT TO IMPORT: the semaglutide 1.0 and 2.4 mg SC weekly arms in the BELIEVE trial (PMID:41772149) are semaglutide's doses, not this compound's.

References